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Objectives. This study sought to compare the frequency of 
restenosis, reocclasion and adverse cardiovascular events after 
angioplasty of occluded versus nonoccluded coronary arteries. 
Background. Angioplasty of chronically occluded coronary ar- 
teries is believed to be associated with a higher frequency of 
restenosis and reocclusion than angioplasty of subtotal stenoses. 
Whether this leads to adverse cardiovascular events is unknown. 
Methods. The Multicenter American Research Trial With 
Cilazapril After Angioplasty to Prevent Restenosis (MARCATOR) 
was a placebo-controlled trial with angiographic follow-up to 
determine the effect of the angiotensin-converting e zyme inhibi- 
tor cilazapril on the frequency of restenosis. In this trial, reste- 
nosis was defined as 1) angiographic reduction of minimal umen 
diameter >0.72 mm between angioplasty and the follow-up visit; 
and 2) >50% diameter stenosis on the follow-up angiogram. We 
identified 139 patients with successful angioplasty of a coronary 
occlusion (Group 1) and compared the frequency of restenosis, 
reocclusion and adverse cardiovascular events with that in 1,295 
patients with successful angioplasty ofa subtotal stenosis (Group 2). 
Results. Restenosis occurred in 36 patients with occluded 
arteries (29%) versus 264 with nonoccluded arteries (23%, p = 
0.177) by definition 1 and in 62 patients with occluded arteries 
(49%) versus 478 with nonoccluded arteries (42%, p = 0.119) by 
definition 2. Occlusion was present in 24 Group 1 patients (19%) 
compared with 74 Group 2 patients (7%) (p < 0.001). During the 
6 month follow-up eriod, two Group 1 patients (1.4%) and six 
Group 2 patients (0.5%) died; no Group 1 patients and 10 Group 
2 patients (0.8%) developed severe congestive heart failure; non- 
fatal myocardial infarction occurred in 4 Group 1 patients (2.9%) 
and 31 Group 2 patients (2.4%); repeat coronary angioplasty or 
bypass urgery was performed in29 Group 1 patients (21%) and 232 
Group 2 patients (18%); and angina was present in 18 Group 1 and 
163 Group 2 patients (13% for both). Eighty-six Group 1 patients 
(62%) and 853 Group 2 patients (66%) remained free of these 
adverse vents during the 6-month follow-up eriod (p = 0.513). 
Conclusions. The frequency of restenosis was slightly but not 
significantly greater after successful angioplasty of an occluded 
artery than after angioplasty ofa subtotal stenosis. Although reoc- 
clusion was more frequent, occurring in 19% of patients, the net 
clinical benefit of angioplasty in such patients was similar to that in 
patients with subtotal stenoses over the 6-month follow-up eriod. 
(JAm CoU Cardiol 1996;27:1-7) 
Percutaneous transluminal coronary angioplasty of chronically 
occluded arteries is associated with a lower initial success rate 
than angioplasty of arteries that are stenotic but not occluded 
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(1-9). In addition, when angioplasty is successful, the fre- 
quency of restenosis and reocclusion has been reported to be 
considerably higher than that after angioplasty of subtotal 
stenoses (2,10,11). In view of these reports, it has been 
suggested that angioplasty of chronically occluded arteries not 
be performed (12), despite vidence that such patients have a 
significant reduction in angina and need for coronary artery 
bypass urgery in the years after the procedure (1,11). 
However, the true restenosis and reocclusion rates after 
angioplasty of an occluded artery is unknown because of the 
small numbers of patients in previous tudies and incomplete 
angiographic follow-up (2,10,11). One recent large study (13) 
with a high rate of angiographic follow-up reported a reocclu- 
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sion rate of 19% for patients undergoing angioplasty of a 
coronary occlusion; however, whether restenosis and reocclu- 
sion lead to adverse cardiovascular events in such patients 
remains unclear. 
The Multicenter American Research Trial With Cilazapril 
After Angioplasty to Prevent Restenosis (MARCATOR) (14) 
was a prospective, randomized trial in which 1,436 patients 
were enrolled after successful coronary angioplasty to deter- 
mine whether treatment with the angiotensin-converting en-
zyme inhibitor cilazapril reduced the frequency of restenosis 
on follow-up coronary angiography 6 months after angioplasty. 
The results of the study revealed that therapy with cilazapril 
did not prevent restenosis and did not favorably influence the 
overall clinical outcome after coronary angioplasty. In the trial, 
139 patients underwent successful coronary angioplasty of an 
occluded coronary artery, and 1,295 underwent angioplasty of 
a subtotal coronary stenosis. 
We performed a data bank study of the MARCATOR trial 
to determine the frequency of restenosis, reocclusion and 
adverse cardiovascular events at 6-month follow-up angiogra- 
phy in patients with successful coronary angioplasty of a 
coronary occlusion versus those with successful angioplasty of 
a subtotal stenosis. 
Methods 
Study patients. The MARCATOR study was a prospec- 
tive, randomized trial in which 1,436 patients at 41 participat- 
ing centers were enrolled after successful coronary angioplasty 
and randomly assigned to one of three dosages of the 
angiotensin-converting enzyme inhibitor cilazapril (1, 5 or 
10 mg orally twice a day) or matching placebo. The inclusion 
criteria for MARCATOR were age 25 to 80 years, no myocar- 
dial infarction within the preceding 5 days and no severe 
valvular disease, severe hypertension, previous revasculariza- 
tion procedure or recent treatment with an angiotensin- 
converting enzyme inhibitor. The primary aim of the study was 
to determine whether treatment with cilazapril reduced the 
frequency of restenosis on routine follow-up coronary angio- 
gram 6 months after the initial angioplasty procedure. In the 
study, 139 patients underwent coronary angioplasty of an 
occluded coronary artery, and 1,295 underwent angioplasty of 
a subtotal stenosis. Two patients with missing data were 
excluded from analysis. Because the results of MARCATOR 
revealed no difference in frequency of restenosis between the 
patients assigned to cilazapril and placebo, all patients were 
included for analysis in the current study, regardless of which 
treatment arm they were assigned to. 
Medical therapy. In addition to the assigned study medi- 
cation, all patients received 325 mg of aspirin before the 
angioplasty procedure and daily throughout the 6-month 
follow-up period. A calcium channel blocking agent was given 
before and for at least 24 h after the angioplasty procedure. All 
other medical therapy was at the discretion of the treating 
physician. 
Definitions. Occlusion = complete absence of anterograde 
flow beyond acoronary stenosis; single-vessel disease = ->50% 
narrowing of a major coronary artery or one of its major 
branches; multivessel disease = presence of a second lesion 
->50% diameter stenosis in a major coronary or in one of its 
major branches; successful angioplasty = residual diameter 
stenosis <50% by visual assessment of the immediate postan- 
gioplasty angiogram at the clinical site. 
Immediate outcome. Angioplasty success was determined 
immediately after completion of the angioplasty procedure at 
the clinical site at which it was performed. The adverse vent 
committee of MARCATOR considered periprocedural myo- 
cardial infarction after the initially successful angioplasty pro- 
cedure to have occurred in patients with prolonged chest pain 
suggestive ofmyocardial ischemia, electrocardiograms (ECGs) 
revealing ischemic changes and elevation of creatine phos- 
phokinase l vels to greater than two times the upper limit of 
normal. Myocardial infarction was considered to have oc- 
curred whether or not Q waves developed on ECG. Patients in 
whom angiographic success was achieved were still eligible for 
inclusion in the trial, even if a periprocedural myocardial 
infarction was believed to have occurred. 
Quantitative angiography. Coronary angiograms were ob- 
tained before, immediately after and 6 months after angio- 
plasty. A standardized method of data acquisition was used to 
ensure accurate reproducibility of the angiograms, as previ- 
ously described (15,16). All cineangiograms were analyzed 
using the Cardiovascular Angiographic Analysis System 
(CAAS), as previously described in the MERCATOR trial 
(17). The absolute values for minimal lumen diameter, as well 
as reference diameter, were measured by computer using the 
catheter diameter without contrast medium as a scaling device. 
Coronary occlusions were assigned a value of 0 mm for 
minimal lumen diameter and 100% for percent diameter 
stenosis. In these cases, the postangioplasty reference diameter 
was used as the reference diameter at follow-up. If repeat 
angioplasty was required for clinical indications before the 
routine 6-month follow-up angiogram, measurements of the 
dilated arterial segment were obtained from the angiogram 
immediately before the second angioplasty procedure regard- 
less of when in the follow-up period it was performed. Patients 
who did not undergo follow-up angiography were excluded 
from this analysis; imputation of angiographic data was not 
performed. For patients with more than one dilated vessel, 
only the most severe stenosis was analyzed. 
Definition of restenosis. In MARCATOR and the present 
analysis, restenosis was prospectively defined in two ways: 1) 
loss in minimal umen diameter ->0.72 mm between postan- 
gioplasty and follow-up angiography; and 2) diameter stenosis 
>50% at follow-up angiography. In MARCATOR, treatment 
effects of cilazapril were tested by the chi-square test, and no 
difference in frequency of restenosis between patients assigned 
to cilazapril and those assigned to placebo was found using 
either definition of restenosis (p = 0.83 for definition 1; p = 
0.41 for definition 2). 
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Follow-up. All patients underwent outpatient evaluation 1,
4, 12, 16 and 24 weeks after angioplasty; no patient was lost to 
follow-up. Follow-up angiography was performed 6 months 
after angioplasty. Adverse events included as end points in this 
analysis were 1) death, 2) New York Heart Association class 
III or IV congestive heart failure, 3) nonfatal myocardial 
infarction, 4) repeat coronary angioplasty or coronary artery 
bypass urgery, and 5) recurrent angina (Canadian Cardiovas- 
cular Society class II or higher) requiring initiation or an 
increase in medical therapy compared with that at 1 week after 
coronary angioplasty. Patients with more than one adverse 
event were assigned the highest ranked event hat occurred, 
according to the previous list of end points. Myocardial 
infarction was considered to have occurred in patients with 
chest pain thought o represent myocardial ischemia, ECG 
changes and elevation of serum creatine phosphokinase to
levels greater than or equal to two times normal. All myocar- 
dial infarctions were adjudicated by an adverse outcome 
committee. 
An analysis was performed to determine whether there had 
been clinical benefit from the angioplasty procedure. At the 
24-week visit before repeat coronary angiography, patients 
who were free of the aforementioned adverse vents were said 
to have derived clinical benefit from angioplasty. 
Statistical methods. The present analysis is based on one 
lesion per patient. For patients undergoing dilation of more 
than one lesion, the "worst" lesion was used. The worst lesion 
was considered to be a total occlusion, if one was present, or 
the lesion with the largest change in stenosis from postangio- 
plasty to follow-up angiography. 
Continuous variables are presented as medians (25th, 75th 
percentiles). Discrete variables are expressed as frequencies 
(percentages). 
Differences in continuous variables between Groups 1 and 
2 were tested using the Wilcoxon rank-sum test. Differences in 
discrete variables were tested by the chi-square test. Results 
were interpreted as statistically significant at p < 0.05. 
Results 
Baseline characteristics. Analysis of the baseline clinical 
characteristics ofthe study revealed that their median age was 
59 years; 80% were male (Table 1). Patients who underwent 
angioplasty of a coronary occlusion were more likely to have a 
history of myocardial infarction (55% vs. 45% for patients with 
nonoccluded arteries, p = 0.018). Myocardial infarction oc- 
curred a median of 71 days before the angioplasty procedure in
patients with an occlusion. Single-vessel disease was present in 
58% of all patients. The median duration of angina was 120 
days. 
Angiographic and procedural characteristics. The propor- 
tion of patients who underwent angioplasty of the left anterior 
descending, circumflex and right coronary arteries was similar 
in both groups (Table 2). Patients who underwent angioplasty 
of a coronary occlusion tended to have undergone angioplasty 
of a second coronary lesion more frequently than patients 
Table 1. Baseline Clinical Characteristics of Study Patients 
Subtotal 
Occlusion Stenosis 
(n = 139) (n = 1,295) 
Age (yr) 54 (47, 62) 59 (51, 66) 
Male 122 (88%) 1,029 (79%) 
Prior MI 77 (55%)* 581 (45%) 
Days since prior MI 71 (24, 222) 58 (11, 1002) 
Prior MI within 2 wk 15 (11%) 176 (14%) 
Prior MI >2 wk earlier 59 (43%) 396 (31%) 
Single-vessel disease 85 (61%) 753 (58%) 
Multivessel disease 54 (39%) 542 (42%) 
CCS angina class 
I 10 (8%) 95 (8%) 
II 45 (35%) 374 (31%) 
III 38 (29%) 332 (27%) 
IV 36 (28%) 409 (34%) 
Angina at rest 52 (37%) 600 (47%) 
Duration of angina (d) 104 (37, 377) 121 (22, 971) 
History of diabetes 18 (13%) 181 (14%) 
Current smoker 22 (20%) 272 (27%) 
*p = 0.018. Data presented are medians (25th, 75th percentiles) or number 
(percent) of patients. CCS = Canadian Cardiovascular Society; d = days; MI = 
myocardial infarction. 
undergoing angioplasty of a subtotal stenosis (39% vs. 24%, 
p < 0.001). More balloon inflations were performed, and total 
inflation time and duration of the procedure were longer in 
patients with coronary occlusions as well. 
After angioplasty, patients with a coronary occlusion had 
had a significantly smaller reference vessel diameter (2.5 vs. 
2.7 ram, p < 0.0001), smaller minimal lumen diameter (1.5 vs. 
1.7 mm, p = 0.0001) and greater esidual diameter stenosis 
(37% vs. 34%, p = 0.0004) than patients with subtotal stenosis. 
However, although these differences were statistically signifi- 
cant, the absolute differences were very small. 
The cumulative distribution curve of the reference vessel 
size immediately after coronary angioplasty is presented in 
Figure 1. Fifty percent of the occluded vessels had a reference 
vessel size -<2.45 ram. Figure 2 shows the cumulative distribu- 
tion of the minimal umen diameter immediately after coro- 
nary angioplasty. Figure 3 shows the cumulative distribution of 
the lumen diameter stenosis immediately after coronary angio- 
plasty. 
In-hospital complications. After successful angioplasty, 
adverse vents during the remainder of the hospital period 
were infrequent in both groups. There were no deaths. Myo- 
cardial infarction occurred in 2 patients in Group 1 (1.4%) and 
20 in Group 2 (1.5%). Repeat coronary angioplasty was 
performed in 4 Group 1 (2.9%) and 25 Group 2 patients 
(1.9%); bypass surgery was not performed in any Group 1 
versus 4 Group 2 patients (0.3%). Angiographic evidence of 
thrombus was present in 13 Group 1 (9%) versus 49 Group 2 
patients (3.8%, p = 0.002); coronary embolization was diag- 
nosed in 0% of Group 1 versus 0.2% of Group 2 patients. 
Results of follow-up angiography. A similar proportion of 
patients in both groups underwent follow-up angiography, and 
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Table 2. Baseline Angiographic and Procedural Characteristics of 
Study Patients 
Subtotal 
Occlusion Stenosis 
(n - 139) (n = 1,295) 
Artery dilated 
LAD 44 (32%) 517 (40%) 
RCA 52 (37%) 458 (35%) 
Cx 43 (31%) 320 (25%) 
No. of lesions dilated 
1 86 (62%)* 981 (76%) 
2 41 (30%) 247 (19%) 
->3 12 (9%) 67 (5%) 
Balloon/artery atio NA 1.1 (1.0, 1.2) 
No. of inflations 5 (3, 7) 3 (2, 5) 
Total inflation time (s) 375 (250, 690) 295 (194, 450) 
Reference diameter 
(mm) 
Pre-PTCA NA 2.6 (2.3, 3.0) 
Post-PTCA 2.5 (2.1, 2.8)? 2.7 (2.3, 3.1) 
Stenosis 
Pre-PTCA 100 (100, 100) 60 (53, 66) 
Post-PTCA 37 (31, 44):~ 34 (29, 40) 
MLD (mm) 
Pre-PTCA 0 (0, 0) 1.0 (0.9, 1.2) 
Post-PTCA 1.5 (1.3, 1.8)+ 1.7 (1.5, 2.0) 
*p = 0.001. tP - 0.000l. :~p = 0.0004. Data presented are medians (25th, 
75th percentiles) or number (%) of patients. LAD = left anterior descending 
coronary artery; Cx = circumflex coronary artery; MLD = minimal umen 
diameter; NA = not applicable; PTCA = percutaneous transluminal coronary 
angioplasty; RCA - right coronary artery. 
the duration of time to follow-up angiography was also similar 
between the two groups (Table 3). The median lumen diame- 
ter stenosis in Group 1 patients was more severe (50% vs. 47%, 
p = 0.0068), and minimal umen diameter was narrower in 
Group 1 patients as well (1.2 vs. 1.4 ram, p = 0.0027). 
Restenosis tended to occur more frequently in Group 1 than 
Group 2 patients. Restenosis occurred in 29% of Group 1 
patients versus 23% of Group 2 patients when defined as a loss 
in minimal lumen diameter ->0.72 mm between postangio- 
plasty and follow-up angiography (p = 0.177) and in 49% of 
1.0 - --' .... 
0.8- __ 
0.6 
% 
0.4 
0.2 S " -- Subtotal stenosis 
 ;,on ...... 
o o ; 1 ~ ; 
MLD after PTCA (mm) 
Figure 2. Cumulative distribution of minimal umen diameter (MLD) 
immediately after coronary angioplasty (PTCA). 
Group 1 patients versus 42% of group 2 patients (p = 0.119) 
when defined as a lesion >50% on follow-up angiography. 
Occlusion was more likely to be present in Group 1 patients 
(19% vs. 7% in Group 2 patients, p = 0.001). 
Figure 4 reveals the cumulative distribution of minimal 
lumen diameter at 6-month follow-up angiography. The cumu- 
lative distribution curve of lumen diameter stenosis at 6-month 
follow-up angiography is presented inFigure 5; 19% of Group 
1 patients had recurrent occlusion at follow-up angiography. 
Figure 6 reveals the cumulative distribution curve of the 
change in lumen diameter stenosis between the immediate 
postangioplasty and the 6-month follow-up angiogram. Ap- 
proximately 20% of patients had either no loss or an increase 
in lumen diameter between the two angiograms. 
Adverse events during follow-up. There was no difference 
in the frequency of adverse cardiovascular events between the 
two groups of patients 6 months after the angioplasty proce- 
dure (Table 4). Two Group l (1.4%) and 6 Group 2 patients 
(0.5%) died during the follow-up period. A similar proportion 
of patients in Groups 1 and 2 developed functional class III or 
IV congestive heart failure (0% vs. 1%), had a myocardial 
infarction (3% vs. 2%), required repeat coronary angioplasty 
or bypass surgery (21% vs. 18%) or developed Canadian 
Cardiovascular Society class II angina or higher (13% vs. 13%) 
Figure 1. Cumulative distribution curve of reference vessel size im- 
mediately after percutaneous transluminal coronary angioplasty 
(PTCA). Fifty percent of occluded vessels had a reference v ssel size 
---2.45 mm. 
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Figure 3. Cumulative distribution of lumen diameter stenosis mme- 
diately after coronary angioplasty (PTCA). 
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Table 3. Frequency, Timing and Results of Follow-Up Angiography 
Subtotal 
Occlusion Stenosis 
(n - 139) (n = 1,295) p Valuc 
Pts with follow-up angiography 126 (91%) 1,138 (88%) 
Days to follow-up angiography 170 (147, 176) 169 (147, 182) 
Reference vessel diameter (mm) 2.6 (2.3, 2.9) 2.7 (2.3, 3.1) 
Mean stenosis (%) 50 (39, 67) 47 (37, 59) 0.0068 
Post-follow-up stenosis loss 12 (l, 33) 13 (2, 24) 0.304 
MLD 1.2 (0.9, 1.6) 1.4 (1.0, 1.7) 0.0027 
Post-follow-up MLD loss 0.31 (-0.04, 0.89) 0.34 (0.07, 0.70) 0.56l 
Restenosis 
->0.72-mm loss in MLD 36 (29%) 264 (23%) 0.177 
>50% stenosis 62 (49%) 478 (42%) 0.119 
Occlusion present (%) 24 (19%) 74 (7%) 0.001 
Data presented are medians (25th, 75th percentiles) or number (%) of patients (Pts). MLD = minimal uminal 
diameter. 
during the follow-up period. Sixty-two percent of Group 1 
patients and 66% of Group 2 patients were free of all adverse 
cardiovascular end points (p = 0.513). Patients with more than 
one adverse event were assigned the highest ranked event, 
according to the previously listed study end points. 
Discussion 
The results of the present study reveal that he frequency of 
angiographic restenosis at 6 months tends to be greater in 
patients with successful coronary angioplasty of a total occlu- 
sion than in those with successful angioplasty of subtotal 
stenoses and that the frequency of occlusion is significantly 
greater (19% vs. 7%, p = 0.001). However, despite the greater 
reocclusion rate, adverse cardiovascular events are no more 
frequent in such patients, and the proportion of patients that 
derive clinical benefit from a successful angioplasty procedure 
is similar in both groups of patients. 
Risks and benefits of dilation of occluded arteries. Angio- 
plasty of chronically occluded arteries is associated with a 
lower initial success rate than angioplasty of subtotal occlu- 
sions (1-9). In patients with successful angioplasty, restenosis 
Figure 4. Cumulative distribution curve of minimal lumen diameter 
(MLD) on 6-month follow-up angiography. 
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rates are high, averaging 46% in several previously reported 
series, with reocclusion in 17% of patients (1,2,4,7). In view of 
the lower primary success rate, the higher estenosis rate and 
the increased time, expense and radiation exposure to both 
patients and physicians associated with angioplasty of occluded 
coronary arteries (18), some have questioned whether angio- 
plasty of occluded coronary arteries hould be performed (12). 
Conversely, several results of angioplasty of occluded coronary 
arteries must be emphasized. 
1. The complication rate is lower than that for angioplasty 
of subtotal occlusions (1-9). The average mortality rate asso- 
ciated with attempted angioplasty of occluded arteries is < 1% 
(1-9), and the frequency of emergency bypass urgery is also 
low, averaging 2% (1,3,5-9). In many cases, the mortality rate 
and frequency of emergency bypass surgery resulting from 
angioplasty of occluded arteries is actually the result of com- 
plications of angioplasty of subtotally occluded arteries per- 
formed during the same procedure (1). 
2. The previously reported high restenosis rates after an- 
gioplasty of occluded coronary arteries may be inaccurate 
because follow-up angiography rates were low in these studies, 
ranging between 27% and 71% (1,2,4,5,8,10). This biases those 
Figure 5. Cumulative distribution curve of lumen diameter stenosis on 
6-month follow-up angiography; 19% of Group 1 patients had recur- 
rent occlusion on follow-up angiography. 
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Figure 6. Cumulative distribution curve of change indiameter stenosis 
between immediate postangioplasty and 6-month follow-up angiogra- 
phy. Approximately 20% of patients had either no loss or an increase 
in lumen diameter between the two angiograms. PTCA = percutane- 
ous transluminal coronary angioplasty. 
Table 4. Adverse Cardiovascular Events (in order of rank) During 
Follow-Up Period* 
Subtotal 
Occlusion Stenosis 
(n = 139) (n - 1,295) 
[no. (%) of pts] [no. (%) of pts] 
Death 2 (1.4) 6 (0.5) 
Congestive heart failure 0 (0) 10 (0.8) 
Myocardial infarction 4 (2.9) 31 (2.4) 
PTCA/CABG 29 (21) 232 (18) 
Recurrent angina 18 (13) 163 (13) 
Event free 86 (62) 853 (66) 
*Patients (pts) with more than one adverse vent were assigned the highest 
ranked event hat occurred, p 0.513 for entire six-level composite nd point. 
CABG = coronary artery bypass graft surgery; PTCA = percutaneous translu- 
minal coronary angioplasty. 
studies toward higher restenosis rates than actually exist 
because patients with recurrent symptoms are more likely to 
undergo follow-up angiography, and most will have restenosis. 
Most asymptomatic patients who do not undergo coronary 
angiography do not have restenosis or reocclusion. In the 
current trial, most patients (91%) underwent follow-up angiog- 
raphy, and quantitative angiographic analysis was performed. 
Restenosis occurred only slightly more frequently in patients 
with coronary occlusion than in those with subtotal stenoses, 
and the difference did not reach statistical significance. Reoc- 
clusion occurred in 19% of such patients; occlusion occurred in 
only 7% of patients who had subtotal stenoses initially. None- 
theless, the most important finding of the current study is that 
despite the higher reocclusion rate in patients undergoing 
angioplasty of a chronic coronary occlusion, the frequency of 
adverse cardiovascular events was no greater than that in 
patients with subtotal stenoses, and a similar proportion of 
patients in both groups were found to have derived clinical 
benefit from the angioplasty procedure. 
Intracoronary stents. Recent studies have indicated that 
reocclusion and restenosis of chronic oronary occlusions may 
be reduced by the use of intracoronary stents. Preliminary data 
from two recent retrospective studies (19,20) reveal that in 69 
patients with chronic coronary occlusions and stent placement, 
the 6-month reocclusion rate was 5%, and restenosis occurred 
in 23% compared with a reocclusion rate of 28% and resten- 
osis rate of 65% in 399 patients treated with balloon angio- 
plasty alone. Prospective, randomized studies are needed to 
determine whether stents should be routinely used in this 
setting. 
Clinical benefit despite restenosis. It should be empha- 
sized that in patients with successful dilation of an occluded 
coronary artery, substantial clinical benefit may result and 
persist, even if restenosis develops. Restenotic lesions that 
reduce the lumen diameter between 50% and 90% do not 
generally reduce coronary blood flow until heart rate and 
blood pressure significantly increase, as occurs with exercise. 
Indeed, the analysis of clinical benefit in the present rial 
indicates that 62% of patients had sustained clinical benefit 6 
months after the angioplasty procedure, although restenosis 
developed in many of them, regardless of which definition of 
restenosis i used. 
Duration of occlusion. In the present trial, data were not 
collected on the estimated duration of coronary artery occlu- 
sion. Most patients who underwent angioplasty of a coronary 
occlusion had a history of myocardial infarction (55%) and 
single-vessel disease (61%). Prior infarction in these patients 
had occurred a median of 59 days before the angioplasty 
procedure; patients with a myocardial infarction in the preced- 
ing 5 days were not eligible for inclusion in the trial. Therefore, 
the duration of the coronary occlusion is likely to be long term 
in most Group 1 patients; accordingly, the results of the 
present study data should not be applied to patients with less 
chronic coronary occlusions whose outcome may differ from 
patients in the present study. 
Limitations of the study. Because data were not collected 
on the duration of coronary occlusion in the trial, analysis of a 
possible relation between the duration of occlusion and the 
frequency of restenosis could not be performed. The 139 
patients with a total occlusion are too small a group to 
conclusively evaluate factors that influence the risk of reste- 
nosis after coronary angioplasty of coronary occlusions. 
Conclusions. After successful angioplasty of a chronically 
occluded artery, restenosis within 6 months occurred in 29% or 
49% of patients, depending on the definition of restenosis 
used, and reocclusion occurred in 19%. However, the majority 
of such patients (62%,) appear to have derived clinical benefit 
from the procedure, and the frequency of adverse cardiovas- 
cular events during the following 6 months was similar to that 
in patients with subtotal stenoses. 
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